JPWO2019241533A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019241533A5 JPWO2019241533A5 JP2020568796A JP2020568796A JPWO2019241533A5 JP WO2019241533 A5 JPWO2019241533 A5 JP WO2019241533A5 JP 2020568796 A JP2020568796 A JP 2020568796A JP 2020568796 A JP2020568796 A JP 2020568796A JP WO2019241533 A5 JPWO2019241533 A5 JP WO2019241533A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- pharmaceutically acceptable
- solvate
- azabicyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 35
- 239000012453 solvate Substances 0.000 claims description 35
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- -1 (methyl) (propa-2-yl) Chemical group 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 14
- 206010015037 epilepsy Diseases 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000001475 halogen functional group Chemical group 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 208000032274 Encephalopathy Diseases 0.000 claims 2
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 claims 2
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000001037 epileptic effect Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- NVZINPVISUVPHW-UHFFFAOYSA-N 3-methylbenzenesulfonamide Chemical compound CC1=CC=CC(S(N)(=O)=O)=C1 NVZINPVISUVPHW-UHFFFAOYSA-N 0.000 claims 1
- WFOIYTFNAZCKMK-UHFFFAOYSA-N 4-[[2-(7-azabicyclo[2.2.1]heptan-7-ylmethyl)-6-fluorophenyl]methylamino]-2-fluoro-3-methyl-N-(1,2-oxazol-3-yl)benzenesulfonamide Chemical compound C1=CC(CN2C3CCC2CC3)=C(CNC2=CC=C(S(=O)(=O)NC=3C=CON=3)C(F)=C2C)C(F)=C1 WFOIYTFNAZCKMK-UHFFFAOYSA-N 0.000 claims 1
- 125000006287 difluorobenzyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 108010052164 Sodium Channels Proteins 0.000 description 6
- 102000018674 Sodium Channels Human genes 0.000 description 6
- CHKFOGJYAICJSR-UHFFFAOYSA-N benzenesulfonamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.NS(=O)(=O)C1=CC=CC=C1 CHKFOGJYAICJSR-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000028329 epileptic seizure Diseases 0.000 description 2
- LTFLHVFIGUDVEV-UHFFFAOYSA-N 4-[[2-(7-azabicyclo[2.2.1]heptan-7-ylmethyl)-6-fluorophenyl]methylamino]-2-fluoro-3-methyl-N-(1,2-oxazol-3-yl)benzenesulfonamide 2,2,2-trifluoroacetic acid Chemical compound FC(C(=O)O)(F)F.C12CCC(CC1)N2CC2=C(CNC1=C(C(=C(C=C1)S(=O)(=O)NC1=NOC=C1)F)C)C(=CC=C2)F LTFLHVFIGUDVEV-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023129150A JP2023138672A (ja) | 2018-06-13 | 2023-08-08 | ベンゼンスルホンアミド化合物および治療剤としてのその使用 |
| JP2025090964A JP2025128218A (ja) | 2018-06-13 | 2025-05-30 | ベンゼンスルホンアミド化合物および治療剤としてのその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684436P | 2018-06-13 | 2018-06-13 | |
| US62/684,436 | 2018-06-13 | ||
| PCT/US2019/037011 WO2019241533A1 (en) | 2018-06-13 | 2019-06-13 | Benzenesulfonamide compounds and their use as therapeutic agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023129150A Division JP2023138672A (ja) | 2018-06-13 | 2023-08-08 | ベンゼンスルホンアミド化合物および治療剤としてのその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021528387A JP2021528387A (ja) | 2021-10-21 |
| JPWO2019241533A5 true JPWO2019241533A5 (https=) | 2022-06-15 |
| JP2021528387A5 JP2021528387A5 (https=) | 2022-06-15 |
| JP7371029B2 JP7371029B2 (ja) | 2023-10-30 |
Family
ID=67138087
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568796A Active JP7371029B2 (ja) | 2018-06-13 | 2019-06-13 | ベンゼンスルホンアミド化合物および治療剤としてのその使用 |
| JP2023129150A Withdrawn JP2023138672A (ja) | 2018-06-13 | 2023-08-08 | ベンゼンスルホンアミド化合物および治療剤としてのその使用 |
| JP2025090964A Pending JP2025128218A (ja) | 2018-06-13 | 2025-05-30 | ベンゼンスルホンアミド化合物および治療剤としてのその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023129150A Withdrawn JP2023138672A (ja) | 2018-06-13 | 2023-08-08 | ベンゼンスルホンアミド化合物および治療剤としてのその使用 |
| JP2025090964A Pending JP2025128218A (ja) | 2018-06-13 | 2025-05-30 | ベンゼンスルホンアミド化合物および治療剤としてのその使用 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10745392B2 (https=) |
| EP (1) | EP3807281A1 (https=) |
| JP (3) | JP7371029B2 (https=) |
| KR (1) | KR102833674B1 (https=) |
| CN (1) | CN112262142B (https=) |
| AU (1) | AU2019285184B2 (https=) |
| BR (1) | BR112020024729A2 (https=) |
| CA (1) | CA3103600A1 (https=) |
| CL (1) | CL2020003197A1 (https=) |
| CR (1) | CR20200613A (https=) |
| EA (1) | EA202092719A1 (https=) |
| EC (1) | ECSP20079861A (https=) |
| IL (1) | IL278949B2 (https=) |
| JO (1) | JOP20200304A1 (https=) |
| MA (1) | MA52888A (https=) |
| MX (1) | MX2020013317A (https=) |
| NI (1) | NI202000098A (https=) |
| PE (1) | PE20211389A1 (https=) |
| PH (1) | PH12020552111A1 (https=) |
| SA (1) | SA520420768B1 (https=) |
| SG (1) | SG11202011862PA (https=) |
| UA (1) | UA127024C2 (https=) |
| WO (1) | WO2019241533A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3458449T3 (pl) * | 2016-05-20 | 2025-06-23 | Xenon Pharmaceuticals Inc. | Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne |
| CN110325531B (zh) | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| US10745392B2 (en) * | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| KR20210054510A (ko) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도 |
| EP4655291A2 (en) * | 2023-01-26 | 2025-12-03 | Merck Sharp & Dohme LLC | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels background |
| CN117510431A (zh) * | 2023-11-08 | 2024-02-06 | 浙江雅辰药物科技股份有限公司 | 一种异噻唑-3-酮及其衍生物、合成方法 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5877193A (en) | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| EP0981327B1 (en) | 1997-05-07 | 2002-11-06 | Galen (Chemicals) Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| DE19907385A1 (de) | 1999-02-20 | 2000-08-24 | Boehringer Ingelheim Pharma | Neue substituierte 3-Phenoxy- und 3-Phenylalkyloxy-2-phenyl-propylamine |
| JP2003504401A (ja) | 1999-07-16 | 2003-02-04 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法 |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| BR0312023A (pt) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
| JP2005162726A (ja) | 2003-01-24 | 2005-06-23 | Tanabe Seiyaku Co Ltd | ピラゾロピリミジン化合物およびその製法 |
| WO2004092123A2 (en) | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibitors of fungal invasion |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| JP2009513523A (ja) | 2003-07-08 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物 |
| US8202861B2 (en) | 2003-08-08 | 2012-06-19 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| JP2008524244A (ja) | 2004-12-17 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | 水酸化ステロイド脱水素酵素阻害剤 |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| CA2624726A1 (en) | 2005-10-06 | 2007-04-12 | Sanofi-Aventis | 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| NZ593074A (en) | 2005-12-21 | 2012-04-27 | Vertex Pharma | sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels |
| EP2054385A2 (en) | 2006-08-15 | 2009-05-06 | F. Hoffmann-Roche AG | Phenyl, pyridine and quinoline derivatives |
| US7968556B2 (en) | 2006-10-19 | 2011-06-28 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| US8853250B2 (en) | 2007-07-13 | 2014-10-07 | Icagen, Inc. | Sodium channel inhibitors |
| CA2693588C (en) | 2007-07-13 | 2015-11-17 | Icagen, Inc. | Sodium channel inhibitors |
| WO2009013171A2 (en) | 2007-07-24 | 2009-01-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| WO2009099177A1 (ja) | 2008-02-06 | 2009-08-13 | Taisho Pharmaceutical Co., Ltd. | アミノイミダゾール誘導体 |
| NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
| RU2011103451A (ru) | 2008-07-01 | 2012-08-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Гетероциклические производные в качестве модуляторов ионных каналов |
| WO2010029300A1 (en) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Bis aromatic compounds for use in the treatment of inflammation |
| HUE025013T2 (hu) | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| EP2606051B1 (en) | 2010-08-20 | 2016-10-05 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| MX2014001851A (es) | 2011-08-17 | 2014-10-24 | Amgen Inc | Inhibidores del canal de heteroarilo sodio. |
| JP2014532660A (ja) | 2011-10-28 | 2014-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおける選択活性を有するベンゾオキサゾリノン化合物 |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| CN104718188B (zh) | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
| KR102038607B1 (ko) | 2012-10-15 | 2019-10-30 | 주식회사 대웅제약 | 소디움 채널 차단제, 이의 제조방법 및 이의 용도 |
| EP2911668A4 (en) | 2012-10-26 | 2016-07-20 | Merck Sharp & Dohme | BENZOXAZOLINONE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-CONTROLLED SODIUM CHANNELS |
| JP2015535252A (ja) | 2012-10-26 | 2015-12-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおいて選択的活性を有するｎ−置換インダゾールスルホンアミド化合物 |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| WO2014201173A1 (en) | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
| JP6407285B2 (ja) | 2013-09-09 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子 |
| UA120353C2 (uk) | 2013-09-10 | 2019-11-25 | Хромоселл Корпорейшн | Модулятори натрієвого каналу для лікування болю і діабету |
| WO2015078374A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| WO2015077905A1 (en) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
| AU2014370407B2 (en) | 2013-12-23 | 2018-03-29 | Purdue Pharma L.P. | Indazoles and use thereof |
| WO2016177340A1 (zh) | 2015-05-05 | 2016-11-10 | 上海海雁医药科技有限公司 | 双环取代的苯磺酰胺衍生物、其制法与医药上的用途 |
| US10519147B2 (en) | 2015-12-18 | 2019-12-31 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| EP3484464B1 (en) | 2016-03-22 | 2020-10-28 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
| PL3458449T3 (pl) * | 2016-05-20 | 2025-06-23 | Xenon Pharmaceuticals Inc. | Związki benzenosulfonamidowe i ich zastosowanie jako środki terapeutyczne |
| US10836758B2 (en) | 2016-10-27 | 2020-11-17 | Bristol-Myers Squibb Company | Acyl sulfonamide NaV1.7 inhibitors |
| WO2018093694A1 (en) * | 2016-11-17 | 2018-05-24 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| CN110325531B (zh) * | 2016-12-09 | 2022-05-27 | 泽农医药公司 | 苯磺酰胺及其作为治疗剂的用途 |
| US10745392B2 (en) | 2018-06-13 | 2020-08-18 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| KR20210054510A (ko) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도 |
-
2019
- 2019-06-13 US US16/440,459 patent/US10745392B2/en active Active
- 2019-06-13 MA MA052888A patent/MA52888A/fr unknown
- 2019-06-13 CN CN201980039029.1A patent/CN112262142B/zh active Active
- 2019-06-13 EP EP19735024.2A patent/EP3807281A1/en active Pending
- 2019-06-13 UA UAA202008102A patent/UA127024C2/uk unknown
- 2019-06-13 BR BR112020024729-4A patent/BR112020024729A2/pt unknown
- 2019-06-13 WO PCT/US2019/037011 patent/WO2019241533A1/en not_active Ceased
- 2019-06-13 SG SG11202011862PA patent/SG11202011862PA/en unknown
- 2019-06-13 CA CA3103600A patent/CA3103600A1/en active Pending
- 2019-06-13 AU AU2019285184A patent/AU2019285184B2/en active Active
- 2019-06-13 PE PE2020001990A patent/PE20211389A1/es unknown
- 2019-06-13 CR CR20200613A patent/CR20200613A/es unknown
- 2019-06-13 JP JP2020568796A patent/JP7371029B2/ja active Active
- 2019-06-13 EA EA202092719A patent/EA202092719A1/ru unknown
- 2019-06-13 KR KR1020217000602A patent/KR102833674B1/ko active Active
- 2019-06-13 IL IL278949A patent/IL278949B2/en unknown
- 2019-06-13 MX MX2020013317A patent/MX2020013317A/es unknown
- 2019-12-13 JO JOP/2020/0304A patent/JOP20200304A1/ar unknown
-
2020
- 2020-07-13 US US16/927,178 patent/US11325902B2/en active Active
- 2020-12-09 CL CL2020003197A patent/CL2020003197A1/es unknown
- 2020-12-09 PH PH12020552111A patent/PH12020552111A1/en unknown
- 2020-12-10 NI NI202000098A patent/NI202000098A/es unknown
- 2020-12-10 EC ECSENADI202079861A patent/ECSP20079861A/es unknown
- 2020-12-10 SA SA520420768A patent/SA520420768B1/ar unknown
-
2023
- 2023-08-08 JP JP2023129150A patent/JP2023138672A/ja not_active Withdrawn
-
2025
- 2025-05-30 JP JP2025090964A patent/JP2025128218A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021528387A5 (https=) | ||
| AU2016204410B2 (en) | Methods for treating vascular leak syndrome | |
| EP2592073B1 (en) | Human protein tyrosine phosphatase inhibitors and their use | |
| RU2419624C2 (ru) | Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2 | |
| JP2019089866A (ja) | がん細胞の転移を予防するための化合物、組成物および方法 | |
| GB2540638A (en) | Compositions, Formulations and methods for treating ocular diseases | |
| JP2006077019A5 (https=) | ||
| CN1426303A (zh) | 噻唑、咪唑和噁唑化合物以及与蛋白老化相关疾病的治疗 | |
| JPWO2019241533A5 (https=) | ||
| JP2013506713A (ja) | β−セクレターゼ活性を阻害するスルホンアミドピロリジン化合物及びその使用方法 | |
| CN101506180B (zh) | 人蛋白酪氨酸磷酸酶抑制剂及使用方法 | |
| RU2435763C2 (ru) | Ингибиторы тирозинфосфатазы белка человека и способы применения | |
| TW201105337A (en) | Medicine derived from a combination of SGLT1-inhibitor and insulin sensitizer | |
| JP2009513606A5 (https=) | ||
| JPS6132287B2 (https=) | ||
| US20120214802A1 (en) | Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof | |
| JPWO2022211420A5 (https=) | ||
| JPWO2004019946A1 (ja) | 細胞内ナトリウムイオン過蓄積抑制薬 | |
| HK1129387B (en) | Human protein-tyrosine phosphatase inhibitors and methods of use |